- Conditions
- Safety and Tolerability in Healthy Volunteers
- Interventions
- NLY01
- Drug
- Lead sponsor
- Neuraly, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 62
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY3053102, Exenatide ER, Placebo, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Orange, California • Miami, Florida • Orlando, Florida + 2 more
- Conditions
- Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
- Interventions
- Pioglitazone, Exenatide, Pioglitazone and Exenatide
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cocaine Use Disorder
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- Christopher D. Verrico
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Interventions
- BYDUREON, Placebo
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- HM11260C, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, exenatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
- Conditions
- Diabetes Mellitus
- Interventions
- HM11260C, Placebo, Victoza
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- California City, California
- Conditions
- Multiple Sclerosis
- Interventions
- NLY01, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- placebo, Exenatide LAR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 7
- States / cities
- Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more
- Conditions
- Type I Diabetes
- Interventions
- Exenatide (Bydureon®), Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Islet Cell Transplant, Islet Cell Transplant plus
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Children and Adolescent With Type 2 Diabetes
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 16
- States / cities
- Los Angeles, California • New Haven, Connecticut • Iowa City, Iowa + 13 more
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650 60 mcg/day, sitagliptin
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Hayward, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide once weekly, metformin, sitagliptin, pioglitazone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 820 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 18
- States / cities
- Buena Park, California • Los Angeles, California • Valencia, California + 15 more
- Conditions
- Type 2 Diabetes
- Interventions
- HM11260C, liraglutide, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- CA, California
- Conditions
- Type 2 Diabetes
- Interventions
- Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Orlando, Florida
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Exenatide Injection
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islets of Langerhans transplantation
- Biological
- Lead sponsor
- CellTrans Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, long acting release, exenatide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 24
- States / cities
- Encino, California • La Jolla, California • San Diego, California + 21 more
- Conditions
- Diabetes Mellitus
- Interventions
- AC2993 (exenatide), daclizumab (immunosuppressive)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetes
- Interventions
- metformin\pioglitazone\exenatide, metformin, glyburide and glargine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650, glimepiride
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Hayward, California
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- semaglutide, exenatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 76
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Pell City, Alabama + 61 more